Incidence, comorbidities, and treatment patterns of nontuberculous mycobacterial infection in South Korea

• Published in: Medicine (Baltimore) Vol. 98; no. 45; p. e17869
• Main Authors: Kim, Hye Ok, Lee, Kyungjong, Choi, Hee Kyoung, Ha, Sangmi, Lee, Sang Moo, Seo, Gi Hyeon
• Format: Journal Article
• Language: English
• Published: United States the Author(s). Published by Wolters Kluwer Health, Inc 01.11.2019; Wolters Kluwer Health
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antitubercular - therapeutic use; Child; Child, Preschool; Comorbidity; Databases, Factual; Drug Therapy, Combination; Female; Humans; Incidence; Infant; Infant, Newborn; Male; Middle Aged; Mycobacterium Infections, Nontuberculous - epidemiology; Mycobacterium Infections, Nontuberculous - therapy; Observational Study; Republic of Korea - epidemiology; Young Adult; Republic of Korea
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000017869

Nontuberculous mycobacteria (NTM) are important pathogens in humans, and hospital-based studies have shown an increased incidence of NTM infection. However, little is known about the treatment pattern of NTM infection with respect to the number of cases per population in South Korea. This study evaluated the trends in the incidence of NTM infection, respiratory comorbidities, and treatment patterns in South Korea.National claims data from the Health Insurance Review and Assessment service database for the years 2009 to 2015 were reviewed, and codes related to NTM infection, respiratory comorbidities occurring from one year before NTM infection and associated treatments were identified.In total, 52,551 patients were included in the study and the average annual incidence per 100,000 person-years was 12.8. The annual incidence was found to have increased from 6.6 to 26.6 per 100,000 persons. Accompanied comorbidities were tuberculosis (33.7%), followed by bronchial asthma (33.2%), chronic obstructive pulmonary disease (25.6%), and lung cancer (5.8%). A total of 76.6% of patients did not receive any combination treatment within one year after the diagnosis of NTM infection. Macrolide-based treatment was administered to 18.8% of patients.A dramatic increase in the incidence of NTM infection was noted in the population of South Korea. Approximately three-fourth of the patients with NTM infection were clinically observed without treatment for at least 1 year after the identification of NTM infection and most patients who treated NTM infection received macrolide-based combination therapy.